

Following is the author index for volume 168 of the *Journal*, which covers all material from January 2011 through December 2011. The *Journal* no longer prints a subject index. Two-letter abbreviations are used for months. The complete citation for each article is listed under the name of the first author. Coauthors are listed alphabetically with a cross-reference to the first author; cross-references containing multiple first author names separated by semicolons indicate multiple articles by the coauthor. Entries other than Reviews and Overviews and New Research are given the following designations: Commentary (*commentary*), Editorial (*editorial*), Images in Neuroscience (*image, neuro*), Introspections (*introspections*), Treatment in Psychiatry (*treatment in psychiatry*), Clinical Case Conference (*case conf*), Education in Psychiatry (*education in psychiatry*), Images in Psychiatry (*image, psych*), Book Forum (*bk rev*), Letters to the Editor (*letter*), Official Actions (*offacts*), and Supplement (*suppl*). Corrections are cited with the articles to which they refer. Readers can also use the *Journal's* website (ajp.psychiatryonline.org) to search by author, issue, subject, section, or keyword.

A

- Aarts E** *see* Hoogman M
Acquaviva C *see* Fassier T
Adam E *see* Allen MH
Addington J, Cornblatt BA, Cadenhead KS, Cannon TD, McGlashan TH, Perkins DO, Seidman LJ, Tsuang MT, Walker EF, Woods SW, Heinsen R: At clinical high risk for psychosis: outcome for nonconverters. *Au* 800–805
Adler JM: Epistemological tension in the future of personality disorder diagnosis (*letter*). *No* 1221–1222
Agarwal LJ, Berger CE, Gill L: Naltrexone for severe self-harm behavior: a case report (*letter*). *Ap* 437–438
Aggen SH *see* Kendler KS
Agorastos A, Huber CG, Dunker S, Wiedemann K: Reduced pain perception in schizophrenia: a case of an undetected intrathoracic pencil (*letter*). *Au* 854–855
Agrawal A *see* Pergadia ML
Ahlf K *see* Foland-Ross LC
Ait-Daoud N *see* Johnson BA
Aizenstein HJ, Andreescu C, Edelman KL, Cochran JL, Price J, Butters MA, Karp J, Patel M, Reynolds CF III: fMRI correlates of white matter hyperintensities in late-life depression. *Oc* 1075–1082
Ak M *see* Naharci MI
Albrecht U *see* Dong L
Alcon J, Glazier K, Rodriguez C: From clutter to modern art: a Chinese artist's perspective on hoarding behaviors (*image, psych*). *De* 1248
Allen LA *see* Dobkin RD
Allen MH, Debanné M, Lazignac C, Adam E, Dickinson LM, Damsa C: Effect of nicotine replacement therapy on agitation in smokers with schizophrenia: a double-blind, randomized, placebo-controlled study. *Ap* 395–399
Alliey-Rodriguez N *see* Ger-shon ES
Alpert JE *see* Wickramaratne P
Altshuler KZ: *bk rev*, Clarkin JF, Fonagy P, Gabbard GO, eds: Psychodynamic Psychotherapy for Personality Disorders. *Ja* 101–102
Altshuler LL *see* Foland-Ross LC
Alvaro JL *see* De Nadai AS
Alzheimer's Disease Neuroimaging Initiative *see* Thompson WK
American Board of Psychiatry and Neurology: 2010 Annual Report (*off acts*). *Au* 863–868
American Psychiatric Association: APA council reports (*off acts*). *Fe* 219–226
American Psychiatric Association: Reports to the membership (*off acts*). *Se* 998–1004
Ametamey SM *see* Deschwendan A
Amin F *see* Levinson DF
Andero R, Heldt SA, Ye K, Liu X, Armario A, Ressler KJ: Effect of 7,8-dihydroxyflavone, a small-molecule TrkB agonist, on emotional learning. *Fe* 163–172
Andersson G *see* Cuijpers P
Andreassen OA *see* Ingason A
Andreescu C *see* Aizenstein HJ
Ansari MS *see* Woodward ND
Anton RF, Myrick H, Wright TM, Latham PK, Baros AM, Waid LR, Randall PK: Gabapentin combined with naltrexone for the treatment of alcohol dependence. *Jy* 709–717
Appelbaum PS: *bk rev*, van Voren R: Cold War in Psychiatry: Human Factors, Secret Actors. *Mr* 333–334
Appenzeller GN *see* Warner CH
Arias SA, Cohen P, Kwon JS: Clozapine-induced lymphocytic alveolitis (*letter*). *Fe* 210–211
Arias-Vásquez A *see* Bralten J

- Arion D** *see* Curley AA
Armario A *see* Andero R
Arseneault L, Cannon M, Fisher HL, Polanczyk G, Moffitt TE, Caspi A: Childhood trauma and children's emerging psychotic symptoms: a genetically sensitive longitudinal cohort study. *Ja* 65–72
Asafu-Adjei JK *see* Curley AA
Auberson YP *see* Deschwendan A
Aubin H-J, Berlin I, Reynaud M: Current smoking, hypoxia, and suicide (*letter*). *Mr* 326–327
Auther AM *see* Carrión RE
Avery JD, Savitz AJ: A novel use of dignity therapy (*letter*). *De* 1340
Azad A, Martin A: The Yale Child Study Center centennial: 1911–2011 (*image, psych*). *Fe* 123

B

- Baandrup L:** How dosing might influence the conclusion in an antipsychotic polypharmacy effectiveness trial (*letter*). *Oc* 1117
Bakalkin G *see* Dong L
Baldessarini RJ *see* Viguera AC
Baldwin RM *see* Woodward ND
Banas R *see* Müller CA
Banaschewski T *see* Peters J
Barale A, Emmanuele E, Politi P: Aby Warburg, 1866–1929 (*image, psych*). *Au* 782
Barber JP *see* Gerber AJ
Barglow P, Murphy T: An early Greek portrayal of a mad mind (*image, psych*). *Se* 893
Baros AM *see* Anton RF
Bassett AS *see* Chow EWC
Bassett AS: Parental origin, DNA structured, and the schizophrenia spectrum (*editorial*). *Ap* 350–353
Bauer LK *see* Mukherji EH
Bearden CE *see* Mittal VA
Beck AT *see* Shedler J
Beenhakker J *see* Lock J
Beevers CG, Lee H-J, Wells TT, Ellis AJ, Telch MJ: Association of predeployment gaze bias for emotion stimuli with later symptoms of PTSD and depression in soldiers deployed in Iraq. *Jy* 735–741
Ben-Zeev D *see* Swendsen J
Benros ME, Nielsen PR, Nordentoft M, Eaton WW, Dalton SO, Mortensen PB: Autoimmune diseases and severe infections as risk factors for schizophrenia: a 30-year population-based register study. *De* 1303–1310
Bergen SE *see* Levinson DF
Berger CE *see* Agarwal LJ
Bergquist K *see* Rando K
Berlin I *see* Aubin H-J
Berner LA *see* Marsh R
Bernstein CA: Presidential Address: transforming mental health through leadership, discovery, and collaboration. *Oc* 1021–1025
Bernstein J, Friedman RA: Lithium-associated hyperthyroidism treated with lithium withdrawal: a case report (*letter*). *Ap* 438–439
Bernstein LF: *bk rev*, Simon RI, Gold LH, eds: The American Psychiatric Publishing Textbook of Forensic Psychiatry, Second Edition. *Fe* 215–216
Bhagwagar Z *see* Rando K
Biederman J *see* Surman GBH
Bienfait KL *see* Dobkin RD
Bilbao A *see* Dong L
Binder EB *see* Zimmermann P
Binswanger I *see* Nussbaum A
Birmaher B: Remission of a mother's depression is associated with her child's mental health (*editorial*). *Je* 563–565
Black DW *see* Levinson DF
Black KJ: A new (old) treatment option for depression in Parkinson's disease (*editorial*). *Oc* 1015–1016
Blair KS *see* Finger EC
Blair KS, Geraci M, Hollon N, Otero M, DeVido J, Majestic C, Jacobs M, Blair RJR, Pine

- DS:** Response to Hubbeling: Alternative explanation for fMRI findings in social phobia (letter). My 551–552
- Blair KS, Geraci M, Korelitz K, Otero M, Towbin K, Ernst M, Leibenluft E, Blair RJR, Pine DS:** The pathology of social phobia is independent of developmental changes in face processing. No 1202–1209
- Blair RJR** *see* **Blair KS; Finger EC**
- Blanco C:** bk rev, Shrout PE, Keyes KM, Ornstein K: Causality and Psychopathology: Finding the Determinants of Disorders and Their Cures. Au 858–859
- Blazer D** *see* **Cooper C**
- Blomeyer D** *see* **Dong L**
- Bonazza S** *see* **Marconi S**
- Bonetto C** *see* **Ingason A**
- Bookheimer SY** *see* **Foland-Ross LC**
- Boomsma DI** *see* **Pergadia ML**
- Borenstein J:** The Council on Communications (off acts). Fe 221–222
- Bose SK** *see* **Howes OD**
- Bozoglu E** *see* **Naharci MI**
- Braff DL** *see* **Greenwood TA**
- Bralten J, Arias-Vásquez A, Makkinje R, Veltman JA, Brunner HG, Fernández G, Rijpkema M, Franke B:** Association of the Alzheimer's gene *SORL1* with hippocampal volume in young, healthy adults. Oc 1083–1089
- Brassen S** *see* **Peters J**
- Breen G, Webb BT, Butler AW, van den Oord EJJ, Tozzi F, Craddock N, Gill M, Korszun A, Maier W, Middleton L, Mors O, Owen MJ, Cohen-Woods S, Perry J, Galwey NW, Upmanyu R, Craig I, Lewis CM, Ng M, Brewster S, Preisig M, Rietschel M, Jones L, Knight J, Rice J, Muglia P, Farmer AE, McGuffin P:** A genome-wide significant linkage for severe depression on chromosome 3: the Depression Network study. Au 840–847
- Breier A:** Anxiety disorders and antipsychotic drugs: a pressing need for more research (editorial). Oc 1012–1014
- Brenner BE** *see* **Kim N**
- Brent DA** *see* **Posner K**
- Brent D:** Nonsuicidal self-injury as a predictor of suicidal behavior in depressed adolescents (editorial). My 452–454
- Brewster S** *see* **Breen G**
- Brodsky H** *see* **Cooper C**
- Brody B, Leon AC, Kocsis JH:** Antidepressant clinical trials and subject recruitment: just who are symptomatic volunteers? (commentary). De 1245–1247
- Broft A** *see* **Martinez D**
- Brohawn KH** *see* **Shin LM**
- Bromberg U** *see* **Peters J**
- Bromet EJ, Kotov R, Fochtmann IJ, Carlson GA, Tanenberg-Karant M, Ruggero C, Chang S-w:** Diagnostic shifts during the decade following first admission for psychosis. No 1186–1194
- Broms U** *see* **Pergadia ML**
- Brook DW:** bk rev, Kaminer Y, Winters KC, eds: Clinical Manual of Adolescent Substance Abuse Treatment. Au 859–860
- Brown AS:** Further evidence of infectious insults in the pathogenesis and pathophysiology of schizophrenia (editorial). Au 764–766
- Brown GK** *see* **Posner K**
- Brückl T** *see* **Zimmermann P**
- Brugières L** *see* **Quera-Salva M-A**
- Brunner HG** *see* **Bralten J**
- Brzustowicz L, Freedman R:** Digging more deeply for generic effects in psychiatric illness (editorial). Oc 1017–1020
- Buccola NG** *see* **Levinson DF**
- Büchel C** *see* **Peters J**
- Buck A** *see* **Deschwanden A**
- Buckley PJ:** bk rev, Wallace DF: A Supposedly Fun Thing I'll Never Do Again: Essays and Arguments. De 1341–1342
- Buckley PJ:** Paul Cézanne, 1839–1906 (image, psych). Jy 680
- Buitelaar J** *see* **Hoogman M**
- Buitelaar JK** *see* **Poelmans G**
- Burger C** *see* **Deschwanden A**
- Burke AK** *see* **Oquendo MA**
- Bush G** *see* **Shin LM**
- Butler AW** *see* **Breen G**
- Butters MA** *see* **Aizenstein HJ**
- Byerley WF** *see* **Levinson DF**
- C**
- Cabaj RP:** The Council on Advocacy and Government Relations (off acts). Fe 219–220
- Cadenhead KS** *see* **Addington J; Greenwood TA**
- Calder AJ** *see* **Fairchild G**
- Calkins ME** *see* **Greenwood TA**
- Cannon M** *see* **Arseneault L; Clarke MC**
- Cannon TD** *see* **Addington J; Mittal VA**
- Capellari S** *see* **Marconi S**
- Carbonneau R** *see* **Pingault J-B**
- Carlson GA** *see* **Bromet EJ**
- Carpenter KM** *see* **Martinez D**
- Carpenter WT, van Os J:** Response to Rietdijk, Linszen, van der Gaag: Field testing attenuated psychosis syndrome criteria (letter). No 1221
- Carpenter WT, van Os J:** Should attenuated psychosis syndrome be a DSM-5 diagnosis? (commentary). My 460–463
- Carrión RE, Goldberg TE, McLaughlin D, Auther AM, Correll CU, Cornblatt BA:** Impact of neurocognition on social and role functioning in individuals at clinical high risk for psychosis. Au 806–813
- Carroll KM** *see* **Kiluk BD**
- Carter CS** *see* **Ursu S**
- Caspi A** *see* **Zimmermann P**
- Caton CLM** *see* **Drake RE**
- Cella M** *see* **Raballo A**
- Cellard C** *see* **Wykes T**
- Cerda G** *see* **Wickramaratne P**
- Chamberlain SR** *see* **Grant JE**
- Chan CH:** bk rev, Bhugra D, Malik A, Ikko G, eds: Psychiatry's Contract with Society: Concepts, Controversies, and Consequences. No 1227
- Chan RCK** *see* **Lui S**
- Chang S-S, Page A, Gunnell D:** Internet searches for a specific suicide method follow its high-profile media coverage (letter). Au 855–857
- Chang S-w** *see* **Bromet EJ**
- Chapman MR, Vause HE:** Anti-NMDA receptor encephalitis: diagnosis, psychiatric presentation, and treatment (case conf). Mr 245–251
- Chapman MR, Vause HE:** Response to Dhossche, Fink, Shorter, Wachtel: Anti-NMDA receptor encephalitis versus pediatric catatonia (letter). Jy 750–751
- Charach R:** bk rev, Ablon SL: Night Call Poems. De 1343–1344
- Charman T:** The highs and lows of counting autism (editorial). Se 873–875
- Cheng Y-C** *see* **Wu C-S**
- Cheon K-A** *see* **Kim YS**
- Chessick C** *see* **Snavey A**
- Chisolm MS** *see* **Spencer L**
- Chou Y-L** *see* **Pergadia ML**
- Chow EWC, Ho A, Wei C, Voormolen EHJ, Crawley AP, Bassett AS:** Association of schizophrenia in 22q11.2 deletion syndrome and gray matter volumetric deficits in the superior temporal gyrus. My 522–529
- Chu BC** *see* **Mark TL**
- Cichon S** *see* **Dong L; Ingason A**
- Clarke MC, Tanskanen A, Huttunen M, Leon DA, Murray RM, Jones PB, Cannon M:** Increased risk of schizophrenia from additive interaction between infant motor developmental delay and obstetric complications: evidence from a population-based longitudinal study. De 1295–1302 (correction: De 1345)
- Clarke T-K** *see* **Dong L**
- Clasen L** *see* **Mattai A**
- Claustrat B** *see* **Quera-Salva M-A**
- Cloninger CR** *see* **Levinson DF**
- Cochran JL** *see* **Aizenstein HJ**
- Cohen BE** *see* **Duivis HE**
- Cohen P:** Abuse in childhood and the risk for psychotic symptoms in later life (editorial). Ja 7–8
- Cohen SA** *see* **Arias SA**
- Cohen SK:** bk rev, Gold LH, Shuman DW: Evaluating Mental Health Disability in the Workplace: Model, Process, and Analysis. Ap 441–442
- Cohen-Woods S** *see* **Breen G**
- Cohler BJ** *see* **Grunbaum H**
- Colibazzi T** *see* **Wang Z**
- Collier DA** *see* **Ingason A**
- Comer JS, Mojtabai R, Olfson M:** National trends in the antipsychotic treatment of psychiatric outpatients with anxiety disorders. Oc 1057–1065
- Compton MT** *see* **Druss BG**
- Conrod PJ** *see* **Peters J**
- Cook IA** *see* **Rush AJ**
- Cools R** *see* **Hoogman M**
- Cooper C, Katona C, Lyketsos K, Blazer D, Brodaty H, Rabins P, de Mendonça Lima CA, Livingston G:** A systematic review of treatments for refractory depression in older people (reviews and overviews). Jy 681–688
- Coors ME:** bk rev, Peay H, Austin J: How to Talk with Families About Genetics and Psychiatric Illness. Se 994–995
- Cornblatt BA** *see* **Addington J; Carrión RE**
- Correa PR:** Limitations of retrospective research (letter). Ap 436–437
- Correll CU** *see* **Carrión RE**
- Corruble E** *see* **Gressier F**
- Cortelli P** *see* **Marconi S**
- Coryell W:** Diagnostic instability: how much is too much? (editorial). No 1136–1138
- Coryell W:** The search for improved antidepressant strategies: is bigger better? (editorial). Jy 664–666
- Coryell WH** *see* **Fiedorowicz JG**
- Côté SM** *see* **Pingault J-B**
- Covell NH** *see* **Essock SM**
- Covell NH, McEvoy JP, Stroup TS, Schooler NR, Essock SM:** Response to Baandrup: How dosing might influence the conclusion in an antipsychotic polypharmacy

- effectiveness trial (letter). Oc 1117
- Cowan RL** *see* Woodward ND
- Cox BS** *see* Cox DJ
- Cox DJ, Cox B, Cox J**: Self-reported incidences of moving vehicle collisions and citations among drivers with ADHD: a cross-sectional survey across the lifespan (letter). Mr 329–330
- Cox J** *see* Cox DJ
- Craddock N** *see* Breen G; Ingason A
- Craig I** *see* Breen G
- Crawley AP** *see* Chow EWC
- Csernansky JG, Smith MJ**: Thought, feeling, and action in real time—monitoring of drug use in schizophrenia (editorial). Fe 120–122
- Cucchiari J** *see* Meltzer HY
- Cuffe S**: The Council on Children, Adolescents, and Their Families (off acts). Fe 220–221
- Cuijpers P, Geraedts AS, van Oppen P, Andersson G, Markowitz JC, van Straten A**: Interpersonal psychotherapy for depression: a meta-analysis (reviews and overviews). Je 581–592 (correction, Je 652)
- Cummings JR, Druss BG**: bk rev, Stevens RA, Rosenberg CE, Burns LR, eds: History and Health Policy in the United States: Putting the Past Back In. No 1224–1225
- Curley AA, Arion D, Volk DW, Asafu-Adjiei JK, Sampson AR, Fish KN, Lewis DA**: Cortical deficits of glutamic acid decarboxylase 67 expression in schizophrenia: clinical, protein, and cell type-specific features. Se 921–929
- Currier D** *see* Oquendo MA
- Currier GW** *see* Posner K
- Czobor P** *see* Wykes T
- D**
- Dagerman KS** *see* Vigen CLP
- D'Agostino RB** *see* Strom BL
- Dalton SO** *see* Benros ME
- D'Amato T** *see* Fassier T
- Damsa C** *see* Allen MH
- David A** *see* Tsuang D
- de Geus EJC** *see* Pergadia ML
- de Jonge P** *see* Duivis HE
- de Mendonça Lima CA** *see* Cooper C
- De Nadai AS, Storch EA, Alvaro JL**: Development of obsessive-compulsive disorder following a pineal germinoma: a case report (letter). My 550
- de Wit S** *see* Gillan CM
- Debanné M** *see* Allen MH
- Del Debbio A** *see* Dias RS
- Delahanty DL**: Toward the predeployment detection of risk for PTSD (editorial). Ja 9–11
- Delepaul P** *see* Heins M
- Demir O** *see* Naharci MI
- Dempster E** *see* Ingason A
- Denier C** *see* Gressier F
- Denk MC, Rewerts C, Holsboer E, Erhardt-Lehmann A, Turck CW**: Monitoring ketamine treatment response in a depressed patient via peripheral mammalian target of rapamycin activation (letter). Jy 751–752
- Dequardo JR**: bk rev, Aboujaoude E, Koran LM, eds: Impulse Control Disorders. No 1225–1226
- Deschwanden A, Karolewicz B, Feyissa AM, Treyer V, Ametamey SM, Johayem A, Burger C, Auberson YP, Sovago J, Stockmeier CA, Buck A, Hasler G**: Reduced metabotropic glutamate receptor 5 density in major depression determined by [¹¹C]ABP688 PET and post-mortem study. Jy 727–734
- Desrivieres S** *see* Dong L
- Devanand DP, Schultz SK**: Consequences of antipsychotic medication for the dementia patient (editorial). Au 767–769
- DeVido J** *see* Blair KS
- Dhossche D, Fink M, Shorter E, Wachtel LE**: Anti-NMDA receptor encephalitis versus pediatric catatonia (letter). Jy 749–750
- Diao H** *see* Li M
- Dias RS, Lafer B, Joffe H**: Response to Harvey, Kornstein: Determination of premenstrual symptom exacerbations (letter). Se 989–990
- Dias RS, Lafer B, Russo C, Del Debbio A, Nierenberg AA, Sachs GS, Joffe H**: Longitudinal follow-up of bipolar disorder in women with premenstrual exacerbation: findings from STEP-BD. Ap 386–394
- Dickinson LM** *see* Allen MH
- DiClemente CC** *see* Johnson BA
- Dierks T** *see* Homan P
- Dixon L** *see* Goff DC
- Djurovic S** *see* Ingason A
- Dobie DJ** *see* Greenwood TA
- Dobkin RD, Menza M, Allen LA, Gara MA, Mark MH, Tiu J, Bienfait KL, Friedman J**: Cognitive-behavioral therapy for depression in Parkinson's disease: a randomized, controlled trial. Oc 1066–1074
- Dodrill CL, Helmer DA, Kosten TR**: Prescription pain medication dependence (treatment in psychiatry). My 466–471
- Dodrill CL, Helmer DA, Kosten TR**: Response to Lustman, Svrakic, Freedland: Preventing pain medication dependence (letter). Oc 1118–1119
- Dokey A** *see* Spencer L
- Domenech P** *see* Fassier T
- Dong L, Bilbao A, Laucht M, Henriksson R, Yakovleva T, Ridinger M, Desrivieres S, Clarke T-K, Lourdasamy A, Smolka MN, Cichon S, Blomeyer D, Treutlein J, Perreau-Lenz S, Witt S, Leonardi-Essmann F, Wodarz N, Zill P, Soyka M, Albrecht U, Rietschel M, Lathrop M, Bakalkin G, Spanagel R, Schumann G**: Effects of the circadian rhythm gene period 1 (*Per1*) on psychosocial stress-induced alcohol drinking. Oc 1090–1098
- Donix M**: From a clinician's perspective (letter). Ap 436
- Donohue JM** *see* Garfield RL
- Doop M** *see* Woodward ND
- Doruk H** *see* Naharci MI
- Douglas CJ**: Studying the efficacy of psychodynamic psychotherapy (letter). Je 649
- Drake RE, Caton CLM, Xie H, Hsu E, Gorroochurn P, Samet S, Hasin DS**: A prospective 2-year study of emergency department patients with early-phase primary psychosis or substance-induced psychosis. Jy 742–748
- Druss BG** *see* Cummings JR
- Druss BG, von Esenwein SA, Compton MT, Zhao L, Leslie DL**: Budget impact and sustainability of medical care management for persons with serious mental illnesses. No 1171–1178
- Duan J** *see* Levinson DF
- Dubicka B** *see* Wilkinson P
- Dubovsky SL**: bk rev, Light DW, ed: The Risks of Prescription Drugs. Oc 1124–1125
- Ducreux D** *see* Gressier F
- Dudbridge F** *see* Levinson DF
- Duivis HE, de Jonge P, Penninx BW, Na BY, Cohen B, Whooley MA**: Depressive symptoms, health behaviors, and subsequent inflammation in patients with coronary heart disease: prospective findings from the Heart and Soul Study. Se 913–920
- Duncan LE, Keller MC**: A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry (reviews and overviews). Oc 1041–1049
- Dunker S** *see* Agorastos A
- Durand DV** *see* Fassier T
- E**
- Eack SM** *see* Prasad KM
- Eaton WW** *see* Benros ME
- Eddy KT, Rauch SL**: Neuroimaging in eating disorders: coming of age (editorial). No 1139–1141
- Edelman KL** *see* Aizenstein HJ
- Egerton A** *see* Howes OD
- Erhardt-Lehmann A** *see* Denk MC
- Ellis AJ** *see* Beevers CG
- Emmanuele E** *see* Barale A
- Endicott J** *see* Fiedorowicz JG
- Endrass T** *see* Riesel A
- Eng SM** *see* Strom BL
- Epstein DH** *see* Zhang X-I
- Ernst M** *see* Blair KS
- Essock SM** *see* Covell NH
- Essock SM, Hogan MF**: Looking into the health reform crystal ball: seeing more constructive, less expensive management scenarios (editorial). My 449–451
- Essock SM, Schooler NR, Stroup T, McEvoy JP, Rojas I, Jackson C, Covell NH, The Schizophrenia Trials Network**: Effectiveness of switching from antipsychotic polypharmacy to monotherapy. Jy 702–708
- Etkin A, Schatzberg AF**: Common abnormalities and disorder-specific compensation during implicit regulation of emotional processing in generalized anxiety and major depressive disorders. Se 968–978
- Evans A** *see* Shaw P
- Everett A**: The Council on Healthcare Systems and Financing (CHSF) (off acts). Fe 222
- F**
- Faich G** *see* Strom BL
- Fairchild G, Passamonti L, Hurford G, Hagan CC, von dem Hagen EAH, van Goozen SHM, Goodyer IM, Calder AJ**: Brain structure abnormalities in early-onset and adolescent-onset conduct disorder. Je 624–633
- Falissard B** *see* Pingault J-B
- Fanous AH** *see* Levinson DF
- Faraone SV** *see* Surman GBH
- Farmer AE** *see* Breen G
- Fassier T, Guffon N, Acquaviva C, D'Amato T, Durand DV, Domenech P**: Misdiagnosed postpartum psychosis revealing a late-onset urea cycle disorder (case conf). Je 576–580
- Fassler D**: Report of the Treasurer: financial status (off acts). Se 999–1000
- Fava M** *see* Rush AJ; Wickramaratne P

- Federspiel A** *see* **Homan P**
Fenton L: bk rev, Frankland AG: The Little Psychotherapy Book: Object Relations in Practice. Ja 102
Fenton L: bk rev, Hall SS: Wisdom: From Philosophy to Neuroscience. De 1343
Fernández G *see* **Bralten J**
Feyissa AM *see* **Deschwanden A**
Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH: Sub-threshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Ja 40–48
Fineberg NA *see* **Gillan CM**
Finger EC, Marsh AA, Blair KS, Reid ME, Sims C, Ng P, Pine DS, Blair RJR: Disrupted reinforcement signaling in the orbitofrontal cortex and caudate in youths with conduct disorder or oppositional defiant disorder and a high level of psychopathic traits. Fe 152–162
Fink M *see* **Dhossche D**
Fischer J *see* **Foland-Ross LC**
Fish KN *see* **Curley AA**
Fisher HL *see* **Arseneault L**
Fishman MJ, Wu L-T, Woody GE: Buprenorphine for prescription opioid addiction in a patient with depression and alcohol dependence (case conf). Jy 675–679
Flor H *see* **Peters J**
Flury R *see* **Homan P**
Fochtman LJ *see* **Bromet EJ; Yager J**
Fogel BL *see* **Wexler E**
Foland-Ross LC, Thompson PM, Sugar CA, Madsen SK, Shen JK, Penfold C, Ahlf K, Rasser PE, Fischer J, Yang Y, Townsend J, Bookheimer SY, Altschuler LL: Investigation of cortical thickness abnormalities in lithium-free adults with bipolar I disorder using cortical pattern matching. My 530–539
Fombonne E *see* **Kim YS**
Fonagy P *see* **Shedler J**
Frank B *see* **Bralten J; Hoogman M; Ingason A; Poelmans G**
Franklin DL *see* **Maguire GA**
Freedland KE *see* **Lustman PJ**
Freedman J: bk rev, McGilchrist I: The Master and His Emissary: The Divided Brain and the Making of the Modern World. Je 655–656
Freedman R *see* **Brzustowicz L; Greenwood TA; Levinson DF; Pine DS**
Freedman R, Lewis DA, Michels R, Pine DS, Schultz SK, Tamminga CA: 2011 in review (editorial). De 1241–1244
Frese FJ *see* **Green MF**
Friedman AC *see* **Martinez D**
Friedman J *see* **Dobkin RD**
Friedman RA *see* **Bernstein J**
Fromson JA: The Asclepius: the ancient standard of physicians (letter). Jy 752
Frost M *see* **Marcus RM**
- G**
- Gabbard GO** *see* **Shedler J**
Galfalvy HC *see* **Oquendo MA**
Gallinat J *see* **Peters J**
Galwey NW *see* **Breen G**
Gameroff MJ *see* **Wickramaratne P**
Gara MA *see* **Dobkin RD**
Garavan H *see* **Peters J**
Garber J *see* **Wickramaratne P**
Gard MG *see* **Ursu S**
Garfield RL, Zuvekas SH, Lave JR, Donohue JM: The impact of national health care reform on adults with severe mental disorders. My 486–494
Garrett A *see* **Lock J**
Garrett A, Kelly R, Gomez R, Keller J, Schatzberg AF, Reiss AL: Aberrant brain activation during a working memory task in psychotic major depression. Fe 173–182
Gaspi A *see* **Arseneault L**
Gaston JO: Report of the Committee on Bylaws (off acts). Se 1002
Gau SS-F *see* **Wu C-S**
Gau SS-F: Childhood trajectories of inattention symptoms predicting educational attainment in young adults (editorial). No 1131–1133
Geier T *see* **Skodol AE**
Gejman PV *see* **Levinson DF**
Gelenberg AJ *see* **Yager J**
Genolini C *see* **Pingault J-B**
George MS, Post RM: Daily left prefrontal repetitive transcranial magnetic stimulation for acute treatment of medication-resistant depression (treatment in psychiatry). Ap 356–364
Geraci M *see* **Blair KS**
Geraedts AS *see* **Cuijpers P**
Gerber A *see* **Wang Z**
Gerber AJ, Kocsis JH, Milrod BL, Roose SP, Barber JP, Thase ME, Perkins P, Leon AC: A quality-based review of randomized controlled trials of psychodynamic psychotherapy (reviews and overviews). Ja 19–28
Gerber AJ, Kocsis JH, Milrod BL, Roose SP, Barber JP, Thase ME, Perkins P, Leon AC: Response to Douglas: Studying the efficacy of psychodynamic psychotherapy (letter). Je 649–650
Gershon ES, Alliey-Rodriguez N, Liu C: After GWAS: searching for genetic risk for schizophrenia and bipolar disorder (reviews and overviews). Mr 253–256
Geuze E *see* **van Zuiden M**
Giacobbe P *see* **Kennedy SH**
Gibbons CJ *see* **Kiluk BD**
Gibson TM *see* **Mark TL**
Giedd J *see* **Shaw P**
Giegling I *see* **Ingason A**
Gill L *see* **Agarwal LJ**
Gill M *see* **Breen G**
Gillan CM, Pappmeyer M, Morein-Zamir S, Sahakian BJ, Fineberg NA, Robbins TW, de Wit S: Disruption in the balance between goal-directed behavior and habit learning in obsessive-compulsive disorder. Jy 718–726
Gilliam M *see* **Shaw P**
Gitlin MJ *see* **Subotnik KL**
Glazier K *see* **Alcon J**
Glenthøj BY *see* **Ingason A**
Glowinski AL *see* **Pergadia ML**
Goate AM *see* **Pergadia ML**
Goff DC, Dixon L: Antipsychotic polypharmacy: are two ever better than one? (editorial). Jy 667–669
Gogtay N *see* **Mattai A**
Gold AL *see* **Shin LM**
Gold JM: Imaging emotion in schizophrenia: not finding feelings in all the right places (editorial). Mr 237–239
Goldberg TE *see* **Carrión RE**
Golner WS *see* **Rosenthal LJ**
Goldman D: Molecular etiologies of schizophrenia: are we almost there yet? (editorial). Se 879–881
Gomez R *see* **Garrett A**
Gong Q *see* **Lui S**
Goodyer I *see* **Fairchild G; Wilkinson P**
Goradia D *see* **Prasad KM**
Gordon C, Green MD: Do all relapses in schizophrenia warrant resumption of medication? (letter). Se 987
Gordon SD *see* **Pergadia ML**
Gorroochurn P *see* **Drake RE**
Graham BM, Milad MR: The study of fear extinction: implications for anxiety disorders. De 1255–1265
Granberry W *see* **Green MF**
Granholt E *see* **Swendsen J**
Grant BF *see* **Skodol AE**
Grant JD *see* **Pergadia ML**
Grant JE, Odlaug BL, Chamberlain SR: Neurocognitive response to deep brain stimulation for obsessive-compulsive disorder: a case report (letter). De 1338–1339
Green MD *see* **Gordon C**
Green MF *see* **Greenwood TA**
Green MF, Schooler NR, Kern RS, Frese FJ, Granberry W, Harvey PD, Karson CN, Peters N, Stewart M, Seidman LJ, Sonnenberg J, Stone WS, Walling D, Stover E, Marder SR: Evaluation of functionally meaningful measures for clinical trials of cognition enhancement in schizophrenia. Ap 400–407
Greenberg RM: bk rev, Gallo R: Freud's Mexico: Into the Wilds of Psychoanalysis. Ap 440–441
Greenhill L *see* **Posner K**
Greenstein D *see* **Mattai A; Shaw P**
Greenwood TA, Lazzeroni LC, Murray SS, Cadenhead KS, Calkins ME, Dobie DJ, Green MF, Gur RE, Gur RC, Hardiman G, Kelsoe JR, Leonard S, Light GA, Nuechterlein KH, Olincy A, Radant AD, Schork NJ, Seidman LJ, Siever LJ, Silverman JM, Stone WS, Swerdlow NR, Tsuang DW, Tsuang MT, Turetsky BI, Freedman R, Braff DL: Analysis of 94 candidate genes and 12 endophenotypes for schizophrenia from the Consortium on the Genetics of Schizophrenia. Se 930–946
Greissier F, Khlif H, Denier C, Hardy P, Ducreux D, Corruble E: Drug-resistant major depression associated with carotid artery stenosis (letter). Ap 439
Grilo CM *see* **Skodol AE**
Grinker RR *see* **Kim YS**
Grinker RR: bk rev, Mnookin S: The Panic Virus: A True Story of Medicine, Science, and Fear. Mr 332–333
Grootens KP: Oxybutynin for antidepressant-induced hyperhidrosis (letter). Mr 330–331
GROUP Investigators *see* **Ingason A**
Grunebaum H, Cohler BJ: An early study of an intervention with children of psychotic mothers (letter). No 1222–1223
Grunebaum MF *see* **Oquendo MA**
Guarnaccia J *see* **Rando K**
Guffon N *see* **Fassier T**
Guirgis H *see* **McKnight C**
Gunnell D *see* **Chang S-S**
Gur RC *see* **Greenwood TA; Pinkham AE**
Gur RE *see* **Greenwood TA; Pinkham AE**
Gurling H *see* **Ingason A**
Gustafsson O *see* **Ingason A**
- H**
- Haddad PM** *see* **Tiihonen J**
Hagan CC *see* **Fairchild G**
Hagerman R: bk rev, Shapiro BK, Accardo PJ, eds: Neurogenetic Syndromes: Behavioral Issues and Their Treatment. Fe 216–217

- Hakonarson H** *see* **Levinson DF**
Hallmayer J *see* **Thompson WK**
Hamer RH *see* **Stroup TS**
Hamilton SP: A new lead from genetic studies in depressed siblings: assessing studies of chromosome 3 (reviews and overviews). *Au* 783–789
Hansen T *see* **Ingason A**
Hardiman G *see* **Greenwood TA**
Hardy P *see* **Gressier F**
Harkavy-Friedman J *see* **Oquendo MA**
Harned MS, Rizvi SL, Linehan MM: Response to Nepon, Pagura, Sareen: Study limitations in report of suicidal behavior among women with co-occurring PTSD and borderline personality disorder (letter). *Mr* 328–329
Hartley S *see* **Quera-Salva M-A**
Hartmann L: bk rev, Hamburg D: Preventing Genocide: Practical Steps Toward Early Detection and Effective Action (revised and updated). *Se* 992
Harvey A, Kornstein SG: Determination of premenstrual symptom exacerbations (letter). *Se* 989
Harvey PD *see* **Green MF**
Harvey PD, Raykov T, Twamley EW, Vella L, Heaton RK, Patterson TL: Validating the measurement of real-world functional outcomes: phase I results of the VALERO study. *No* 1195–1201
Hasin DS *see* **Skodol AE**
Hasler G *see* **Deschwanden A**
Hasnain M *see* **Vieweg WVR**
Hauf M *see* **Homan P**
Haukka J *see* **Tiihonen J**
Haws CA *see* **Kim N**
Heath AC *see* **Pergadia ML**
Heaton RK *see* **Harvey PD**
Heijnen CJ *see* **van Zuiden M**
Heins M, Simons C, Lataster T, Pfeifer S, Versmissen D, Lardinois M, Marcelis M, Delepaal P, Krabbendam L, van Os J, Myin-Germeyns I: Childhood trauma and psychosis: a case-control and case-sibling comparison across different levels of genetic liability, psychopathology, and type of trauma. *De* 1286–1294
Heinssen R *see* **Addington J**
Heinz A *see* **Peters J**
Heldt SA *see* **Andero R**
Hellmann GS *see* **Subotnik KL**
Helmer DA *see* **Doddrill CL**
Henders AK *see* **Pergadia ML**
Henn FA: Dopamine: a marker of psychosis and final common driver of schizophrenia psychosis (editorial). *De* 1239–1240
Henriksson R *see* **Dong L**
Hermann D *see* **Koopmann A**
Hermida AP *see* **Maixmer DF**
Hershfield B: Report of the Speaker (off acts). *Se* 1001–1002
Hicks MH-R: Mental health screening and coordination of care for soldiers deployed to Iraq and Afghanistan (editorial). *Ap* 341–343
Hirschfeld RMA: Deep brain stimulation for treatment-resistant depression (editorial). *My* 455–456
Ho A *see* **Chow EWC**
Hodges BD *see* **Law SF**
Hoek HW *see* **Veling W**
Hogan MF *see* **Essock SM**
Hoge CW *see* **Warner CH**
Hollon N *see* **Blair KS**
Holmans PA *see* **Levinson DF**
Holsboer F *see* **Denk MC; Zimmermann P**
Homan P, Kindler J, Feder-spiel A, Flury R, Hubl D, Hauf M, Dierks T: Muting the voice: a case of arterial spin labeling-monitored transcranial direct current stimulation treatment of auditory verbal hallucinations (letter). *Au* 853–854 (corrections, *Se* 991; *No* 1223)
Hong K-I *see* **Rando K**
Hoogman M, Aarts E, Zwiers M, Slaats-Willemse D, Naber M, Onnink M, Cools R, Kan C, Buitelaar J, Franke B: Nitric oxide synthase genotype modulation of impulsivity and ventral striatal activity in adult ADHD patients and healthy comparison subjects. *Oc* 1099–1106
Horga G *see* **Marsh R**
Hosanagar A *see* **Mattai A**
Howes OD, Bose SK, Turheimer F, Valli I, Egerton A, Valmaggia LR, Murray RM, McGuire P: Dopamine synthesis capacity before onset of psychosis: a prospective [¹⁸F]-DOPA PET imaging study. *De* 1311–1317
Hreidarsson SJ *see* **Ingason A**
Hsiao JK *see* **Vigen CLP**
Hsu E *see* **Drake RE**
Huang X *see* **Law SF; Lui S**
Hubbeling DAA: Alternative explanation for fMRI findings in social phobia (letter). *My* 551
Huber CG *see* **Agorastos A**
Hubl D *see* **Homan P**
Huddy V *see* **Wykes T**
Hughes CW: Objective assessment of suicide risk: significant improvements in assessment, classification, and prediction (editorial). *De* 1233–1234
Hughes CW *see* **Wickramaratne P**
Hughes KC *see* **Shin LM**
Hurford G *see* **Fairchild G**
Hurst D, Loeffler G, McLay R: Psychosis associated with synthetic cannabinoid agonists: a case series (letter). *Oc* 1119
Husain MM *see* **Maixmer DF; Rush AJ**
Huttunen M *see* **Clarke MC**
Hyman SE: Grouping diagnoses of mental disorders by their common risk factors (editorial). *Ja* 1–3
- I**
- IMAGEN Consortium** *see* **Peters J**
Ingason A, Kirov G, Giegling I, Hansen T, Isles AR, Jakobsen KD, Kristinsson KT, le Roux L, Gustafsson O, Craddock N, Möller H-J, McQuillin A, Muglia P, Cichon S, Rietschel M, Ophoff RA, Djurovic S, Andreassen OA, Pietiläinen OPH, Peltonen L, Dempster E, Collier DA, St. Clair D, Rasmussen HB, Glenthøj Y, Kiemenev LA, Franke B, Tosato S, Bonetto C, Saemundsen E, Hreidarsson SJ, GROUP Investigators, Nöthen MM, Gurling H, O'Donovan MC, Owen MJ, Sigurdsson E, Petersson H, Stefansson H, Rujescu D, Stefansson K, Werge T: Maternally derived micro-duplications at 15q11-q13: implication of imprinted genes in psychotic illness. *Ap* 408–417
Ising M *see* **Zimmermann P**
Isles AR *see* **Ingason A**
Itterman B *see* **Peters J**
- J**
- Jackson C** *see* **Essock SM**
Jacobs M *see* **Blair KS**
Jakobsen KD *see* **Ingason A**
Januzzi JL *see* **Mukherji EH**
Jardri R, Pouchet A, Pins D, Thomas P: Cortical activations during auditory verbal hallucinations in schizophrenia: a coordinate-based meta-analysis. *Ja* 73–81
Javors MA *see* **Johnson BA**
Joffe H *see* **Dias RS**
Johayem A *see* **Deschwanden A**
Johnson B: Response to Müller, Banas: Disulfiram: an anticraving substance? (letter). *Ja* 98–99
Johnson BA, Ait-Daoud N, Seneviratne C, Roache JD, Javors MA, Wang X-Q, Liu L, Penberthy JK, DiClemente CC, Li MD: Pharmacogenetic approach at the serotonin transporter gene as a method of reducing the severity of alcohol drinking. *Mr* 265–275 (correction, *Jy* 756)
Jones L *see* **Breen G**
Jones PB *see* **Clarke MC**
Joshi KG *see* **Romo CA**
- K**
- Kadison R**: bk rev, Kay J, Schwartz V, eds: Mental Health Care in the College Community. *Oc* 1123
Kahn MW: Palliative psychotherapy (introspection). *Se* 888–889
Kalali AH *see* **Meltzer HY**
Kan C *see* **Hoogman M**
Kane JM *see* **Strom BL**
Kaprio J *see* **Pergadia ML**
Karadurmus N *see* **Naharci MI**
Karolewicz B *see* **Deschwanden A**
Karp J *see* **Aizenstein HJ**
Karpf RD *see* **Shin LM**
Karson CN *see* **Green MF**
Kathmann N *see* **Riesel A**
Katona C *see* **Cooper C**
Kaufmann C *see* **Riesel A**
Kavelaars A *see* **van Zuiden M**
Keefe RSE *see* **Vigen CLP**
Keller J *see* **Garrett A**
Keller MB *see* **Fiedorowicz JG**
Keller MC *see* **Duncan LE**
Kelly R *see* **Garrett A**
Kelsoe JR *see* **Greenwood TA**
Kelvin R *see* **Wilkinson P**
Kemp GJ *see* **Lui S**
Kendler KS *see* **Levinson DF**
Kendler KS, Aggen SH, Knudsen GP, Røysamb E, Neale MC, Reichborn-Kjennerud T: The structure of genetic and environmental risk factors for syndromal and subsyndromal common DSM-IV axis I and all axis II disorders. *Ja* 29–39
Kennedy SH, Giacobbe P, Rizvi SJ, Placenza FM, Nishikawa Y, Mayberg HS, Lozano AM: Deep brain stimulation for treatment-resistant depression: follow-up after 3 to 6 years. *My* 502–510
Kern RS *see* **Green MF**
Kernberg O *see* **Shedler J**
Keshavan MS *see* **Prasad KM**
Keskitalo-Voukko K *see* **Pergadia ML**
Kessler RM *see* **Woodward ND**
Keyes KM *see* **Skodol AE**
Khlif H *see* **Gressier F**
Kiefer F *see* **Koopmann A**
Kiemenev LA *see* **Ingason A**
Kiluk BD, Sugarman DE, Nich C, Gibbons CJ, Martino S, Rounsaville BJ, Carroll KM: A methodological analysis of randomized clinical trials of computer-assisted therapies for psychiatric disorders: toward improved standards for an emerging field (reviews and overviews). *Au* 790–799

- Kim N, Mickelson JB, Brenner BE, Haws CA, Yurgelun-Todd DA, Renshaw PF:** Altitude, gun ownership, rural areas, and suicide. *Ja* 49–54
- Kim N, Yurgelun-Todd DA, Renshaw PF:** Response to Aub in, Berlin, Reynaud: Current smoking, hypoxia, and suicide (letter). *Mr* 326–327
- Kim S-J** *see* **Kim YS**
- Kim Y-K** *see* **Kim YS**
- Kim YS, Leventhal BL, Koh Y-J, Fombonne E, Laska E, Lim E-C, Cheon K-A, Kim S-J, Kim Y-K, Lee HK, Song D-H, Grinker RR:** Prevalence of autism spectrum disorders in a total population sample. *Se* 904–912
- Kindler J** *see* **Homan P**
- King C** *see* **Wickramaratne P**
- Kirov G** *see* **Ingason A**
- Kirsten J** *see* **Maguire GA**
- Klahr KW** *see* **Marsh R**
- Kleber HD** *see* **Martinez D**
- Klein RG:** Thinning of the cerebral cortex during development: a dimension of ADHD (editorial). *Fe* 111–113
- Knight J** *see* **Breen G**
- Knudsen GP** *see* **Kendler KS**
- Kocsis JH** *see* **Brody B; Gerber AJ**
- Koh Y-J** *see* **Kim YS**
- Koopman A, von der Goltz C, Hermann D, Kiefer F:** Propofol addiction initiated by anesthetic use (letter). *Fe* 211–212
- Korelitz K** *see* **Blair KS**
- Korhonen P** *see* **Tiihonen J**
- Korhonen T** *see* **Pergadia ML**
- Kornstein SG** *see* **Rush AJ**
- Korszun A** *see* **Breen G**
- Kosten TR** *see* **Doddrill CL**
- Kosten TR:** Stress and addiction (editorial). *Je* 566–5687
- Kotov R** *see* **Bromet EJ**
- Koukopoulos AE** *see* **Viguera AC**
- Krabbendam L** *see* **Heins M**
- Kring AM** *see* **Ursu S**
- Kripal JJ** *see* **Lomax JW**
- Kristinsson KT** *see* **Ingason A**
- Kuang W** *see* **Lui S**
- Kumar D** *see* **Martinez D**
- Kupfer DJ, Regier DA:** Neuroscience, clinical evidence, and the future of psychiatric classification in DSM-5 (commentary). *Jy* 672–674
- Kurian BT** *see* **Rush AJ**
- Kwon JS** *see* **Arias SA**
- L**
- Lafer B** *see* **Dias RS**
- Lalonde F** *see* **Mattai A**
- Lardinois M** *see* **Heins M**
- LaRusso EM:** Happy Mother's Day, with love from the ABPN (introspection). *My* 464–465
- Laska E** *see* **Kim YS**
- Lataster T** *see* **Heins M**
- Latham PK** *see* **Anton RF**
- Lathrop M** *see* **Dong L; Peters J**
- Laucht M** *see* **Dong L**
- LaVange LM** *see* **Stroup TS**
- Lave JR** *see* **Garfield RL**
- Law SF, Liu P, Hodges BD, Shera W, Huang X, Zaheer J, Links PS:** Introducing psychiatry to rural physicians in China: an innovative education project (education in psychiatry). *De* 1249–1254
- Lawlor DA** *see* **McGrath JJ**
- Lazignac C** *see* **Allen MH**
- Lazzeroni LC** *see* **Greenwood TA**
- Le Foll B** *see* **Lev-Ran S**
- le Roux L** *see* **Ingason A**
- Le Strat Y** *see* **Lev-Ran S**
- Lebowitz BD** *see* **Vigen CLP**
- Lee H-J** *see* **Beevers CG**
- Lee HB:** My father's shoes (introspection). *Oc* 1031–1032
- Lee HK** *see* **Kim YS**
- Leibenluft E** *see* **Blair KS**
- Leibenluft E:** Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths (reviews and overviews). *Fe* 129–142
- Leon AC** *see* **Brody B; Fiedorowicz JG; Gerber AJ**
- Leon DA** *see* **Clarke MC**
- Leonard S** *see* **Greenwood TA**
- Leonardi-Essmann F** *see* **Dong L**
- Lepri B** *see* **Viguera AC**
- Leskov I** *see* **Mukherji EH**
- Leslie DL** *see* **Druss BG**
- Lesser IM** *see* **Rush AJ**
- Lev-Ran S, Le Strat Y, Le Foll B:** Impact of hypertension and body mass index on quality of life in schizophrenia (letter). *My* 552–553
- Leventhal BL** *see* **Kim YS**
- Levinson DE, Duan J, Oh S, Wang K, Sanders AR, Shi J, Zhang N, Mowry BJ, Olincy A, Amin E, Cloninger CR, Silverman JM, Buccola NG, Byerley WF, Black DW, Kendler KS, Freedman R, Dudgeon F, Pe'er I, Hakonarson H, Bergen SE, Fanous AH, Holmans PA, Gejman PV:** Copy number variants in schizophrenia: confirmation of five previous findings and new evidence for 3q29 microdeletions and VIPR2 duplications. *Mr* 302–316
- Lewis CM** *see* **Breen G**
- Lewis DA** *see* **Curley AA; Freedman R**
- Li C-SR** *see* **Rando K**
- Li M, Luo X, Xiao X, Shi L, Liu X, Yin L, Diao H, Su B:** Allelic differences between Han Chinese and Europeans for functional variants in ZNF804A and their association with schizophrenia. *De* 1318–1325
- Li MD** *see* **Johnson BA**
- Li R** *see* **Woodward ND**
- Lieb R** *see* **Zimmermann P**
- Lieberman JA** *see* **Roberts CE; Stroup TS**
- Lieberman JA, Stroup TS:** The NIMH-CATIE schizophrenia study: what did we learn? (commentary). *Au* 770–775
- Lieberman JA, Winstead D:** The Council on Research and Quality Care (off acts). *Fe* 225–226
- Light GA** *see* **Greenwood TA**
- Lim E-C** *see* **Kim YS**
- Linehan MM** *see* **Harned MS**
- Links PS** *see* **Law SF**
- Linszen D** *see* **Rietdijk J**
- Lipsitt DR:** Moments of (in) decision (introspection). *Au* 776–777
- Liu C** *see* **Gershon ES**
- Liu F** *see* **Martinez D**
- Liu JZ** *see* **Pergadia ML**
- Liu L** *see* **Johnson BA**
- Liu P** *see* **Law SF**
- Liu S, Wu Q, Qiu L, Yang X, Kuang W, Chan RCK, Huang X, Kemp GJ, Mechelli A, Gong Q:** Resting-state functional connectivity in treatment-resistant depression. *Je* 642–648
- Liu X** *see* **Andero R; Li M**
- Liverpool M** *see* **Shaw P**
- Livingston G** *see* **Cooper C**
- Lock J, Garrett A, Beenhakker J, Reiss AL:** Aberrant brain activation during a response inhibition task in adolescent eating disorder subtypes. *Ja* 55–64
- Loebel A** *see* **Meltzer HY**
- Loeffler G** *see* **Hurst D**
- Lomax JW, Kripal JJ, Pargament KI:** Perspectives on “sacred moments” in psychotherapy (case conf). *Ja* 12–18
- Loth E** *see* **Peters J**
- Loughead J** *see* **Pinkham AE**
- Loukola A** *see* **Pergadia ML**
- Lourdusamy A** *see* **Dong L**
- Lozano AM** *see* **Kennedy SH**
- Lu L** *see* **Zhang X-I**
- Luo X** *see* **Li M**
- Lustman PJ, Svrakic DM, Freedland KE:** Preventing pain medication dependence (letter). *Oc* 1118
- Luther JF** *see* **Rush AJ**
- Lyketsos CG** *see* **Spencer L; Vigen CLP**
- Lyketsos K** *see* **Cooper C**
- M**
- Maas M** *see* **van Zuiden M**
- MacGregor S** *see* **Pergadia ML**
- Mack WJ** *see* **Vigen CLP**
- Macklin ML** *see* **Shin LM**
- Madden PAF** *see* **Pergadia ML**
- Madsen SK** *see* **Foland-Ross LC**
- Maguire GA, Franklin DL, Kirsten J:** Asenapine for the treatment of stuttering: an analysis of three cases (letter). *Je* 651–652
- Maia TV** *see* **Wang Z**
- Maier W** *see* **Breen G**
- Maixner DE, Hermida AP, Husain MM, Rudowski MR, Reti IM:** Succinylcholine short-acting and electroconvulsive therapy (letter). *Se* 986–987
- Majestic C** *see* **Blair KS**
- Makkinje R** *see* **Bralten J**
- Malek M** *see* **Shaw P**
- Malloy E** *see* **Wickramaratne P**
- Mann JJ** *see* **Oquendo MA; Posner K**
- Marcelis M** *see* **Heins M**
- Marconi S, Rizzo G, Capellari S, Scaglione C, Cortelli P, Martinelli P, Bonazza S:** Eating disorder as a psychiatric onset of juvenile Huntington's disease (letter). *Oc* 1120–1121
- Marcus MD:** bk rev, Karasu SR, Karasu TB: The Gravity of Weight: A Clinical Guide to Weight Loss and Maintenance. *Je* 654
- Marcus RM, Sanchez R, Frost M, McQuade RD:** Aripiprazole adjunctive to antidepressant therapy (letter). *Fe* 211
- Marder S** *see* **Green MF; Subotnik KL**
- Mark MH** *see* **Dobkin RD**
- Mark TL, Gibson TM, McGuigan K, Chu BC:** Response to Correa: Limitations of retrospective research (letter). *Ap* 437
- Markowitz JC** *see* **Cuijpers P**
- Markowitz JC, Milrod BL:** The importance of responding to negative affect in psychotherapies (education in psychiatry). *Fe* 124–128
- Marks DJ** *see* **Solanto MV**
- Marsh AA** *see* **Finger EC**
- Marsh R** *see* **Wang Z**
- Marsh R, Horga G, Wang Z, Wang P, Klahr KW, Berner LA, Walsh BT, Peterson BS:** An fMRI study of self-regulatory control and conflict resolution in adolescents with bulimia nervosa. *No* 1210–1220
- Martin A** *see* **Azad A**
- Martin NG** *see* **Pergadia ML**
- Martinelli P** *see* **Marconi S**
- Martinez D, Carpenter KM, Liu F, Shifstein M, Broft A, Friedman AC, Kumar D, Van Heertum R, Kleber HD, Nunes E:** Imaging dopamine transmission in cocaine dependence: link between neurochemistry and response to treatment. *Je* 634–641
- Martino S** *see* **Kiluk BD**
- Martinot J-L** *see* **Peters J**

- Martis B:** Cracking the code: dopamine signaling in cocaine dependence (editorial). *Je* 572–575
- Mataix-Cols D** *see* Nakao T
- Matejkowski J, Cullen S, Solomon P:** Comment on the association of stigma with violence (letter). *Jy* 749
- Mattai A, Hosanagar A, Weisinger B, Greenstein D, Stidd R, Clasen L, Lalonde F, Rapoport J, Gogtay N:** Hippocampal volume development in healthy siblings of childhood-onset schizophrenia patients. *Ap* 427–435
- Mayberg HS** *see* Kennedy SH
- McEvoy JP** *see* Covell NH; Essock SM; Stroup TS
- McGlashan TH** *see* Addington J; Woods SW
- McGrath JJ, Lawlor DA:** The search for modifiable risk factors for schizophrenia (editorial). *De* 1235–1238
- McGuffin P** *see* Breen G
- McGuigan K** *see* Mark TL
- McGuire P** *see* Howes OD
- McGurk SR** *see* Wykes T
- McKnight C, Guirgis H, Votolato N:** Clozapine rechallenge after excluding the high-risk clozapine-induced agranulocytosis genotype of HLA-DQB1 6672GT>C (letter). *Oc* 1120
- McLaughlin D** *see* Carrión RE
- McLay R** *see* Hurst D
- McQuade RD** *see* Marcus RM
- McQuillin A** *see* Ingason A
- Mechelli A** *see* Lui S
- Medland SE** *see* Pergadia ML
- Meltzer HY, Cucchiari J, Silva R, Ogasa M, Phillips D, Xu J, Kalali AH, Schweizer E, Pikalov A, Loebel A:** Lurasidone in the treatment of schizophrenia: a randomized, double-blind, placebo- and olanzapine-controlled trial. *Se* 957–967
- Melvin GA** *see* Posner K
- Menz M** *see* Peters J
- Menza M** *see* Dobkin RD
- Merrill DB** *see* Roberts CE
- Michels R** *see* Freedman R; Shedler J
- Mickelson JB** *see* Kim N
- Middleton L** *see* Breen G
- Milad MR** *see* Graham BM; Shin LM
- Miller CA** *see* Surman GBH
- Milofsky JE:** bk rev, Lazar SG, ed: *Psychotherapy Is Worth It: A Comprehensive Review of Its Cost-Effectiveness*. *Ja* 102–103
- Milrod BL** *see* Gerber AJ; Markowitz JC
- Mintz J** *see* Subotnik KL
- Minzenberg MJ** *see* Ursu S
- Mital VA, Cannon TD, Bearden CE:** Response to De Nadai, torch, Alvaro: Development of obsessive-compulsive disorder following a pineal germinoma: a case report (letter). *My* 550–551
- Moffitt TE** *see* Arseneault L; Zimmermann P
- Mogul KM:** Report of the Elections Committee (off acts). *Se* 1004
- Mojtabai R** *see* Comer JS
- Möller H-J** *see* Ingason A
- Monteggia LM:** Toward neurotrophin-based therapeutics (editorial). *Fe* 114–116
- Montgomery GW** *see* Pergadia ML
- Morein-Zamir S** *see* Gillan CM
- Morris DW** *see* Rush AJ
- Mors O** *see* Breen G
- Mortensen PB** *see* Benros ME; Pedersen MG; Petersen L
- Mortenson LY** *see* Roberts CE
- Mowry BJ** *see* Levinson DF
- Mrazek DA:** bk rev, Shaw RJ, DeMaso DR, eds: *Textbook of Pediatric Psychosomatic Medicine*. *Ap* 442–443
- Muglia P** *see* Breen G; Ingason A
- Mukherji EH, Bauer LK, Leskov I, Januzzi JL, Tanev KS:** Safety of antipsychotics in the setting of QTc prolongation: the utility of the JT index (letter). *Se* 990–991
- Müller CA, Banas R:** Disulfiram: an anticraving substance? (letter). *Ja* 98
- Murphy T** *see* Barglow P
- Murray RM** *see* Clarke MC; Howes OD
- Murray SS** *see* Greenwood TA
- Myin-Germeys I** *see* Heins M
- Myrick H** *see* Anton RF
- N**
- Na BY** *see* Duivis HE
- Naber M** *see* Hoogman M
- Naharci MI, Karadurmus N, Demir O, Bozoglu E, Ak M, Doruk H:** Fatal hepatotoxicity in an elderly patient receiving low-dose quetiapine (letter). *Fe* 212–213
- Nakao T, Radua J, Rubia K, Mataix-Cols D:** Gray matter volume abnormalities in ADHD: voxel-based meta-analysis exploring the effects of age and stimulant medication (reviews and overviews). *No* 1154–1163
- Neale MC** *see* Kendler KS
- Nelson EC** *see* Pergadia ML
- Nepon J, Pagura J, Sareen J:** Study limitations in report of suicidal behavior among women with co-occurring PTSD and borderline personality disorder (letter). *Mr* 328
- Newton TF:** bk rev, Renner JA, Levounis P: *Handbook of Office-Based Buprenorphine Treatment of Opioid Dependence*. *Je* 654–655
- Ng M** *see* Breen G
- Ng P** *see* Finger EC
- Nich C** *see* Kiluk BD
- Nielsen PR** *see* Benros ME
- Nierenberg AA** *see* Dias RS; Rush AJ
- Nimgaonkar VL** *see* Prasad KM
- Nishikawa Y** *see* Kennedy SH
- Nocon A** *see* Zimmermann P
- Nordentoft M** *see* Benros ME
- Norgaard-Pedersen B** *see* Pedersen MG
- Nöthen MM** *see* Ingason A
- Nuechterlein KH** *see* Greenwood TA; Subotnik KL
- Nunes E** *see* Martinez D
- Nurnberger J:** bk rev, Coons PM, Bowman ES: *Psychiatry in Indiana: the First 175 Years*. *Se* 995–996
- Nussbaum A, Thurstone C, Binswanger I:** Medical marijuana use and suicide attempt in a patient with major depressive disorder (case conf). *Au* 778–781
- Nussbaum AM** *see* Stroup TS
- O**
- O'Brien CP:** Adapting treatment to patient problems (editorial). *Jy* 670–671
- Occhiogrosso M** *see* Wender P
- Odlaug BL** *see* Grant JE
- O'Donovan MC** *see* Ingason A
- Ogasa M** *see* Meltzer HY
- Oh S** *see* Levinson DF
- O'Hara R** *see* Thompson WK
- Oldham JM:** Response to Presidential Address. *Oc* 1026–1028
- Olsson M** *see* Comer JS
- Olincy A** *see* Greenwood TA; Levinson DF
- Ongur D:** bk rev, Stroup TS, Lieberman JA, eds: *Antipsychotic Trials in Schizophrenia: The CATIE Project*. *Mr* 334
- Onnink M** *see* Hoogman M
- Onhoff RA** *see* Ingason A
- Oquendo MA** *see* Posner K
- Oquendo MA, Galfalvy HC, Currier D, Grunebaum ME, Sher L, Sullivan GM, Burke AK, Harkavy-Friedman J, Sublette ME, Parsey RV, Mann JJ:** Treatment of suicide attempters with bipolar disorder: a randomized clinical trial comparing lithium and valproate in the prevention of suicidal behavior. *Oc* 1050–1056
- O'Reardon JP** *see* Rosenthal LJ
- Orr SP** *see* Shin LM
- Otero M** *see* Blair KS
- Overton E** *see* Pinkham AE
- Owen MJ** *see* Breen G; Ingason A
- P**
- Page A** *see* Chang S-S
- Pagura J** *see* Nepon J
- Pancholi KM** *see* Prasad KM
- Papmeyer M** *see* Gillan CM
- Parellada M:** bk rev, Hollander E, Kolevzon A, Coyle JT, eds: *Textbook of Autism Spectrum Disorders*. *My* 554–555
- Pargament KI** *see* Lomax JW
- Park S** *see* Woodward ND
- Parker GB:** bk rev, Davidson J: *Downing Street Blues: A History of Depression and Other Mental Afflictions in British Prime Ministers*. *Jy* 753–754
- Parker JR** *see* Warner CH
- Parsey RV** *see* Oquendo MA
- Passamonti L** *see* Fairchild G
- Patel M** *see* Aizenstein HJ
- Patel MX** *see* Tihihonen J
- Patterson TL** *see* Harvey PD
- Pauls DL** *see* Poelmans G
- Paus T** *see* Peters J
- Payne J:** Bipolar disorder in women with premenstrual exacerbation (editorial). *Ap* 344–346
- Pedersen CB** *see* Pedersen MG; Petersen L
- Pedersen MG, Stevens H, Pedersen CB, Norgaard-Pedersen B, Mortensen PB:** *Toxoplasma* infection and later development of schizophrenia in mothers. *Au* 814–821
- Peele R:** Report of the Secretary: actions of the Board of Trustees (off acts). *Se* 998–999
- Pe'er I** *see* Levinson DF
- Peltonen L** *see* Ingason A
- Penberthy JK** *see* Johnson BA
- Penfold C** *see* Foland-Ross LC
- Penninx BW** *see* Duivis HE; Pergadia ML
- Pergadia ML, Glowinski AL, Wray NR, Agrawal A, Saccone SF, Loukola A, Broms U, Korhonen T, Penninx BWJH, Grant JD, Nelson EC, Henders AK, Schrage AJ, Chou Y-L, Keskitalo-Vuokko K, Zhu Q, Gordon SD, Vink JM, de Geus EJC, MacGregor S, Liu JZ, Willemsen G, Medland SE, Boomsma DI, Montgomery GW, Rice JP, Goate AM, Heath AC, Kaprio J, Martin NG, Madden PAF:** A 3p26-3p25 genetic linkage finding for DSM-IV major depression in heavy smoking families. *Au* 848–852
- Perkins DO** *see* Addington J; Stroup TS
- Perkins P** *see* Gerber AJ
- Perlis RH:** Betting on biomarkers (editorial). *Mr* 234–236
- Perlis RH:** Hard outcomes: clinical trials to reduce suicide (editorial). *Oc* 1009–1011

- Perreau-Lenz S** *see* Dong L
Perry J *see* Breen G
Pescosolido BA: Response to Torrey: The association of stigma with violence (letter). *Mr* 325–326
Peters J, Bromberg U, Schneider S, Brassen S, Menz M, Banaschewski T, Conrod PJ, Flor H, Gallinat J, Garavan H, Heinz A, Itterman B, Lathrop M, Martinot J-L, Paus T, Poline J-B, Robbins TW, Rietschel M, Smolka M, Ströhle A, Struve M, Loth E, Schumann G, Büchel C, IMAGEN Consortium: Lower ventral striatal activation during reward anticipation in adolescent smokers. *My* 540–549
Peters N *see* Green MF
Petersen L, Mortensen PB, Pedersen CB: Paternal age at birth of first child and risk of schizophrenia. *Ja* 82–88
Peterson BS *see* Wang Z
Petersson H *see* Ingason A
Petty CR *see* Surman GBH
Pfeifer S *see* Heins M
Pfister H *see* Zimmermann P
Phillips D *see* Meltzer HY
Pies R: The ruined good boy (introspection). *No* 1145–1146
Pietiläinen OPH *see* Ingason A
Pilalov A *see* Meltzer HY
Pilowsky DJ *see* Wickramaratne P
Pine DS *see* Blair KS; Finger EC; Freedman R
Pine DS, Freedman R: Imagining a brighter future (editorial). *Se* 885–887
Pingault J-B, Tremblay RE, Vitaro F, Carbonneau R, Genolini C, Falissard B, Côté SM: Childhood trajectories of inattention and hyperactivity and prediction of educational attainment in early adulthood: a 16-year longitudinal population-based study. *No* 1164–1170
Pinkham AE, Loughhead J, Ruparel K, Overton E, Gur RE, Gur RC: Abnormal modulation of amygdala activity in schizophrenia in response to direct- and averted-gaze threat-related facial expressions. *Mr* 293–301
Pins D *see* Jardri R
Pitman RK *see* Shin LM
Placenza FM *see* Kennedy SH
Poelmans G, Pauls DL, Buite-laar JK, Franke B: Integrated genome-wide association study findings: identification of a neurodevelopmental network for attention deficit hyperactivity disorder (reviews and overviews). *Ap* 365–377
Polanczyk G *see* Arseneault L
Poline J-B *see* Peters J
Politi P *see* Barale A
Posner K, Brown GK, Stanley B, Brent DA, Yershova KV, Oquendo MA, Currier GW, Melvin GA, Greenhill L, Shen S, Mann JJ: The Columbia–Suicide Severity Rating Scale: initial validity and internal consistency findings from three multisite studies with adolescents and adults. *De* 1266–1277
Post RM *see* George MS
Pouchet A *see* Jardri R
Prasad KM, Eack SM, Goradia D, Pancholi KM, Keshavan MS, Yolken RH, Nimgaonkar VL: Progressive gray matter loss and changes in cognitive functioning associated with exposure to herpes simplex virus 1 in schizophrenia: a longitudinal study. *Au* 822–830
Preisig M *see* Breen G
Preti A *see* Raballo A
Price J *see* Aizenstein HJ
- Q**
- Qiu L** *see* Lui S
Quera-Salva M-A, Hartley S, Claustrat B, Brugières L: Circadian rhythm disturbances associated with psychiatric symptoms in a patient with a pineal region tumor (letter). *Ja* 99–100
- R**
- Raballo A, Cella M, Preti A**: The pulse of thought: hemodynamics of the brain and mind (image, psych). *No* 1152–1153
Rabins P *see* Cooper C
Radant AD *see* Greenwood TA
Radua J *see* Nakao T
Rafizadeh N *see* Roberts CE
Ragland JD *see* Ursu S
Raine A: An amygdala structural abnormality common to two subtypes of conduct disorder: a neurodevelopmental conundrum (editorial). *Je* 569–571
Randall PK *see* Anton RF
Rando K, Hong K-I, Bhagwagar Z, Li C-SR, Bergquist K, Guarnaccia J, Sinha R: Association of frontal and posterior cortical gray matter volume with time to alcohol relapse: a prospective study. *Fe* 183–192
Rapoport J *see* Mattai A; Shaw P
Rasmussen HB *see* Ingason A
Rasser PE *see* Foland-Ross LC
Rauch SL *see* Eddy KT; Shin LM
Raykov T *see* Harvey PD
- Recupero PR**: The Council on Psychiatry and the Law (off acts). *Fe* 225
Regier DA *see* Kupfer DJ
Reginaldi D *see* Viguera AC
Reichborn-Kjennerud T *see* Kendler KS
Reid ME *see* Finger EC
Reiss AL *see* Garrett A; Lock J
Reite M: bk rev, Monti JM, Pandi-Perumal SR, Möhler H, eds: GABA and Sleep: Molecular, Functional and Clinical Aspects. *Jy* 755
Renner JA *see* Wise TN
Renshaw PF *see* Kim N
Ressler KJ *see* Andero R
Reti IM *see* Maixner DF
Rewerts C *see* Denk MC
Reynaud M *see* Aubin H-J
Reynolds CF III *see* Aizenstein HJ
Reynolds RF *see* Strom BL
Rice J *see* Breen G; Pergadia ML
Ridinger M *see* Dong L
Riesel A, Endrass T, Kaufmann, Kathmann N: Overactive error-related brain activity as a candidate endophenotype for obsessive-compulsive disorder: evidence from unaffected first-degree relatives. *Mr* 317–324
Rietdijk J, Linszen D, van der Gaag M: Field testing attenuated psychosis syndrome criteria (letter). *No* 1221
Rietschel M *see* Breen G; Dong L; Ingason A; Peters J
Rijkema M *see* Bralten J
Ring KD *see* Stroup TS
Rizvi SJ *see* Kennedy SH
Rizvi SL *see* Harned MS
Rizzo G *see* Marconi S
Roache JD *see* Johnson BA
Robbins M: bk rev, Starzl TE: The Puzzle People: Memoirs of a Transplant Surgeon. *My* 556–557
Robbins TW *see* Gillan CM; Peters J
Roberts C *see* Wilkinson P
Roberts CE, Mortenson LY, Merrill DEB, Rafizadeh N, Smith TE, Lieberman JA: Successful rechallenge with clozapine after eosinophilia (case conf). *No* 1147–1151
Robinowitz CB: Carol A Bernstein, 137th President, 2010–2011. *Oc* 1029–1030
Robinson DG: Medication adherence and relapse in recent-onset psychosis (editorial). *Mr* 240–242
Rodriguez C *see* Alcon J
Rogers SJ: bk rev, Treffert D: Islands of Genius: The Bountiful Mind of the Autistic, Acquired, and Sudden Savant. *Au* 860–861
Rojas I *see* Essock SM
Romo CA, Joshi KG, Waters BM: Involuntary movements associated with cetirizine use (letter). *Au* 855
Roose SP *see* Gerber AJ
Rosenbaum JF: bk rev, Warner J: We've Got Issues: Children and Parents in the Age of Medication. *Fe* 214–215
Rosenheck RA *see* Stroup TS
Rosenthal LJ, Goldner WS, O'Reardon JP: T₃ augmentation in major depressive disorder: safety considerations (treatment in psychiatry). *Oc* 1035–1040
Rostov D *see* Spencer L
Rounsaville BJ *see* Kiluk BD
Royamb E *see* Kendler KS
Rubia K *see* Nakao T
Rubin JEV: Report of the Membership Committee (off acts). *Se* 1002–1004
Rudowski MR *see* Maixner DF
Ruggero C *see* Bromet EJ
Ruiz P: bk rev, Reznick L: Delusions and the Madness of the Masses. *Ap* 440
Rujescu D *see* Ingason A
Ruparel K *see* Pinkham AE
Rush A, Trivedi MH, Stewart JW, Nierenberg AA, Fava M, Kurian BT, Warden D, Morris DW, Luther JE, Husain MM, Cook IA, Shelton RC, Lesser IM, Kornsterin SG, Wisniewski SR: Combining Medications to Enhance Depression Outcomes (CO-MED): acute and long-term outcomes of a single-blind randomized study. *Jy* 689–701
Rush AJ *see* Wickramaratne P
Ruskin J *see* Strom BL
Russo C *see* Dias RS
- S**
- Saccone SF** *see* Pergadia ML
Sachs GS *see* Dias RS
Saemundsen E *see* Ingason A
Sahakian BJ *see* Gillan CM
Samet S *see* Drake RE
Sampson AR *see* Curley AA
Samstad E *see* Spencer L
Sanchez R *see* Marcus RM
Sanders AR *see* Levinson DF
Sano M *see* Vigen CLP
Sareen J *see* Nepon J
Sasin DS *see* Drake RE
Sato M: The short-term effect of the recent great earthquake on the general functioning status of psychiatric patients near Tokyo (letter). *Je* 649
Savin D: bk rev, Niaz U: Wars, Insurgencies, and Terrorist Attacks: A psychosocial Perspective From the Muslim World. *Je* 653–654
Savitz AJ *see* Avery JD
Scaglione C *see* Marconi S
Schabbing M: bk rev, Janicak PG, Marder SR, Pavuluri MN:

- Principles and Practice of Psychopharmacotherapy, Fifth Edition. Au 861
- Schatzberg AF** *see* **Etkin A; Garrett A**
- Schechter MA**: Nicotine replacement therapy in the psychiatric emergency department (editorial). Ap 347–349
- Schizophrenia Trials Network** *see* **Essock SM; Stroup TS**
- Schneck C**: Bipolar phenomenology: have we learned all we can learn? (editorial). Ja 4–6
- Schneider LS** *see* **Vigen CLP**
- Schneider S** *see* **Peters J**
- Schooler NR** *see* **Covell NH; Essock SM; Green MF**
- Schork NJ** *see* **Greenwood TA**
- Schrage AJ** *see* **Pergadia ML**
- Schroeder SA**: Depression, smoking, and heart disease: how can psychiatrists be effective? (editorial). Se 876–878
- Schultz SK** *see* **Devanand DP; Freedman R**
- Schumann G** *see* **Dong L; Peters J**
- Schweizer E** *see* **Meltzer HY**
- Scully JH Jr**: Report of the Medical Director and CEO (off acts). Se 1000–1001
- Seidman LJ** *see* **Addington J; Green MF; Greenwood TA**
- Selten J-P** *see* **Veling W**
- Seneviratne C** *see* **Johnson BA**
- Seritan AL**: bk rev, Kay J: *Obliquity: Why Our Goals Are Best Achieved Indirectly*. De 1342–1343
- Sexson S**: The Council on Medical Education and Lifelong Learning (off acts). Fe 222–224
- Sharfstein SS**: Integrated care (editorial). No 1134–1135
- Sharp W** *see* **Shaw P**
- Shaw P, Gilliam M, Liverpool M, Weddle C, Malek M, Sharp W, Greenstein D, Evans A, Rapoport J, Giedd J**: Cortical development in typically developing children with symptoms of hyperactivity and impulsivity: support for a dimensional view of attention deficit hyperactivity disorder. Fe 143–151
- Shedler J, Beck AT, Fonagy P, Gabbard GO, Kernberg O, Michels R, Westen D**: Response to Skodol: Revision of the personality disorder model for DSM-5 (letter). Ja 97–98
- Shelton RC** *see* **Rush AJ**
- Shen JK** *see* **Foland-Ross LC**
- Shen S** *see* **Posner K**
- Sher L** *see* **Oquendo MA**
- Shera W** *see* **Law SF**
- Shi J** *see* **Levinson DF; Zhang X-I**
- Shi L** *see* **Li M**
- Shin LM, Bush G, Milad MR, Lasko NB, Brohawn KH, Hughes KC, Macklin RD, Orr SP, Rauch SL, Pitman RK**: Exaggerated activation of dorsal anterior cingulate cortex during cognitive interference: a monozygotic twin study of posttraumatic stress disorder. Se 979–985
- Shorter E** *see* **Dhossche D**
- Siever LJ** *see* **Greenwood TA**
- Sigurdsson E** *see* **Ingason A**
- Silva R** *see* **Meltzer HY**
- Silver JM**: bk rev, Steele CM: *Whistling Vivaldi: And Other Clues to How Stereotypes Affect Us*. My 556
- Silverman JM** *see* **Greenwood TA; Levinson DF**
- Simons C** *see* **Heins M**
- Sims C** *see* **Finger EC**
- Singh IR** *see* **Subotnik KL**
- Singh MK**: bk rev, Brown TE, ed: *ADHD Comorbidities: Handbook for ADHD Complications in Children and Adults*. My 555
- Sinha R** *see* **Rando K**
- Skodol A**: Response to Adler: Epistemological tension in the future of personality disorder diagnosis (letter). No 1222
- Skodol AE, Grilo CM, Keyes KM, Geier T, Grant BF, Hasin DS**: Relationship of personality disorders to the course of major depressive disorder in a nationally representative sample. Mr 257–264
- Skodol AE**: Revision of the personality disorder model for DSM-5 (letter). Ja 97
- Slaats-Willemse D** *see* **Hoogman M**
- Slifstein M** *see* **Martinez D**
- Smith MJ** *see* **Csernansky JG**
- Smith TE** *see* **Roberts CE**
- Smolka M** *see* **Dong L; Peters J**
- Smoller JW**: Do Antidepressants raise the risk of stroke? (editorial). My 457–459
- Snavely A, Chessick C**: bk rev, Hagen R, Turkington D, Berge T, Grawe RW: *CBT for Psychosis: A Symptom-Based Approach*. No 1226–1227
- Solanto MV, Wasserstein J, Marks DJ**: Response to Wells, Fisher: Meta-cognitive therapy without metacognition: a case of ADHD (letter). Mr 327–328
- Solomon DA** *see* **Fiedorowicz JG**
- Solomon M** *see* **Ursu S**
- Song D-H** *see* **Kim YS**
- Sonnenberg J** *see* **Green MF**
- Sood AB** *see* **Wickramaratne P**
- Sorel E**: Report of the Committee of Tellers (off acts). Se 1004
- Sovago J** *see* **Deschanden A**
- Soyka M** *see* **Dong L**
- Spanagel R** *see* **Dong L**
- Spencer L, Lyketsos CG, Samstad E, Kokey A, Rostov D, Chisolm MS**: A suicidal adult in crisis: an unexpected diagnosis of autism spectrum disorder (case conf). Se 890–892
- Spencer T** *see* **Surman GBH**
- St. Clair D** *see* **Ingason A**
- Stanley B** *see* **Posner K**
- Stefansson H** *see* **Ingason A**
- Stefansson K** *see* **Ingason A**
- Steinberg H**: A 200th anniversary of academic psychiatry (image, psych). Oc 1033–1034
- Stern R**: bk rev, Danilowitz B: *The Prints of Josef Albers: A Catalogue Raisonné 1915–1976, Revised Edition*. De 1344–1345
- Stevens H** *see* **Pedersen MG**
- Stewart JW** *see* **Rush AJ**
- Stewart M** *see* **Green MF**
- Stidd R** *see* **Mattai A**
- Stockmeier CA** *see* **Deschanden A**
- Stone WS** *see* **Green MF; Greenwood TA**
- Storch EA** *see* **De Nadai AS**
- Stover E** *see* **Green MF**
- Ströhle A** *see* **Peters J**
- Strom BL, Eng SM, Faich G, Reynolds RF, D'Agostino RB, Ruskin J, Kane JM**: Comparative mortality associated with ziprasidone and olanzapine in real-world use among 18,154 patients with schizophrenia: the Ziprasidone Observational Study of Cardiac Outcomes (ZODIAC). Fe 193–201
- Strom BL, on behalf of the ZODIAC Investigators**: Response to Vieweg, Hain: Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study (letter). Je 651
- Stroup TS** *see* **Covell NH; Essock SM; Lieberman JA; Vigen CLP**
- Stroup TS, McEvoy JP, Ring KD, Hamer RH, LaVange LM, Swartz MS, Rosenheck RA, Perkins DO, Nussbaum AM, Lieberman JA, for the Schizophrenia Trials Network**: A randomized trial examining the effectiveness of switching from olanzapine, quetiapine, or risperidone to aripiprazole to reduce metabolic risk: Comparison of Antipsychotics for Metabolic Problems (CAMP). Se 947–956
- Stroup TS**: What can large simple trials do for psychiatry? (editorial). Fe 117–119
- Struve M** *see* **Peters J**
- Su B** *see* **Li M**
- Sublette ME** *see* **Oquendo MA**
- Subotnik KL, Nuechterlein KH, Ventura J, Gitlin MJ, Marder S, Mintz J, Hellemann GS, Thornton LA, Singh IR**: Risperidone nonadherence and return of positive symptoms in the early course of schizophrenia. Mr 286–292
- Subotnik KL, Nuechterlein KH, Ventura J, Marder S**: Response to Gordon, Gree: Do all relapses in schizophrenia warrant resumption of medication? (letter). Se 987–988
- Sugar CA** *see* **Foland-Ross LC**
- Sugarman DE** *see* **Kiluk BD**
- Sullivan A**: Report of the Speaker-Elect (off acts). Se 1002
- Sullivan GM** *see* **Oquendo MA**
- Sultzer DL** *see* **Vigen CLP**
- Sun L-I** *see* **Zhang X-I**
- Surman GBH, Biederman J, Spencer T, Yorks D, Miller CA, Petty CR, Faraone SV**: Deficient emotional self-regulation and adult attention deficit hyperactivity disorder: a family risk analysis. Je 617–623
- Susser E** *see* **Veling W**
- Svrakic DM** *see* **Lustman PJ**
- Swartz CM**: bk rev, Hersch JK: *Struck by Living: From Depression to Hope*. Jy 754–755
- Swartz MS** *see* **Stroup TS**
- Swendsen J, Ben-Zeev D, Granholm E**: Real-time electronic ambulatory monitoring of substance use and symptom expression in schizophrenia. Fe 202–209
- Swerdlow NR** *see* **Greenwood TA**

T

- Tamminga CA** *see* **Freedman R**
- Tamminga CA**: When is polypharmacy an advantage? (editorial). Jy 663
- Tanenberg-Karant M** *see* **Bromet EJ**
- Tanev KS** *see* **Mukherji EH**
- Tanguay PE**: Autism in DSM-5 (commentary). No 1142–1144
- Tanskanen A** *see* **Clarke MC**
- Tariot PN** *see* **Vigen CLP**
- Taylor M** *see* **Tiihonen J**
- Telch MJ** *see* **Beevers CG**
- Thase ME** *see* **Gerber AJ**
- Thomas P** *see* **Jardri R**
- Thompson PM** *see* **Foland-Ross LC**
- Thompson WK, Hallmayer J, O'Hara R, Alzheimer's Disease Neuroimaging Initiative**: Design considerations for characterizing psychiatric trajectories across the lifespan: application to effects of APOE-ε4 on cerebral cortical

thickness in Alzheimer's disease. Se 894–903
Thornton LA *see* **Subotnik KL**
Thurstone C *see* **Nussbaum A**
Tiihonen J, **Haukka J**, **Taylor M**, **Haddad PM**, **Patel MX**, **Korhonen P**: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. *Je* 603–609
Tiu J *see* **Dobkin RD**
Tohen M: bk rev, Gordon E, Koslow S, eds: Integrative Neuroscience and Personalized Medicine. *Oc* 1123–1124
Tondo L *see* **Viguera AC**
Torrey EF: Response to Matejowski, Cullen, Solomon: Comment on the association of stigma with violence (letter). *Jy* 749
Torrey EF: The association of stigma with violence (letter). *Mr* 325
Tosato S *see* **Ingason A**
Towbin K *see* **Blair KS**
Townsend J *see* **Foland-Ross LC**
Tozzi F *see* **Breen G**
Tremblay RE *see* **Pingault J-B**
Treutlein J *see* **Dong L**
Treyer V *see* **Deschanden A**
Trivedi MH *see* **Rush AJ**; **Wickramaratne P**
Tsuang D, **David A**: bk rev, Flint J, Greenspan RJ, Kendler KS: How Genes Influence Behavior. *Je* 656
Tsuang DW *see* **Greenwood TA**
Tsuang MT *see* **Addington J**; **Greenwood TA**
Turck CW *see* **Denk MC**
Turetsky BI *see* **Greenwood TA**
Turkheimer F *see* **Howes OD**
Twamley EW *see* **Harvey PD**

U

Uhr M *see* **Zimmermann P**
Upmanyu R *see* **Breen G**
Ursu S, **Kring AM**, **Gard MG**, **Minzenberg MJ**, **Yoon JH**, **Ragland JD**, **Solomon M**, **Carter CS**: Prefrontal cortical deficits and impaired cognition-emotion interactions in schizophrenia. *Mr* 276–285

V

Vahia IV: bk rev, Bhattacharya R, Cross S, Bhugra D, eds: Clinical Topics in Cultural Psychiatry. *Ja* 103–104
Vaidya N: An identity crisis (introspection). *Ap* 354
Valli I *see* **Howes OD**
Valmaggia LR *see* **Howes OD**
van den Oord EJCG *see* **Breen G**
van der Gaag M *see* **Rietdijk J**
van Goozen SHM *see* **Fairchild G**

Van Heertum R *see* **Martinez D**
van Oppen P *see* **Cuijpers P**
van Os J *see* **Carpenter WT**; **Heins M**
van Straten A *see* **Cuijpers P**
van Zuiden M, **Geuze E**, **Willemen HLD**, **Vermetten E**, **Maas M**, **Heijnen CJ**, **Kavelaars A**: Pre-existing high glucocorticoid receptor number predicting development of posttraumatic stress symptoms after military deployment. *Ja* 89–96
Vause HE *see* **Chapman MR**
Veling W, **Hoek HW**, **Selten J-P**, **Susser E**: Age at migration and future risk of psychotic disorders among immigrants in the Netherlands: A 7-year incidence study. *De* 1278–1285
Vella L *see* **Harvey PD**
Veltman JA *see* **Bralten J**
Ventura J *see* **Subotnik KL**
Vermetten E *see* **van Zuiden M**
Versmissen D *see* **Heins M**
Vieweg WVR, **Hasnain M**: Question regarding ziprasidone and QTc interval prolongation in the ZODIAC study (letter). *Je* 650–651
Vigen CLP, **Mack WJ**, **Keefe RSE**, **Sano M**, **Sultzer DL**, **Stroup TS**, **Dagerman KS**, **Hsiao JK**, **Lebowitz BD**, **Lyketsos CG**, **Tariot PN**, **Zheng L**, **Schneider LS**: Cognitive effects of atypical antipsychotic medications in patients with Alzheimer's disease: outcomes from CATIE-AD. *Au* 831–839
Viguera AC, **Tondo L**, **Koukopoulos AE**, **Reginaldi D**, **Lepri B**, **Baldessarini RJ**: Episodes of mood disorders in 2,252 pregnancies and postpartum periods. *No* 1179–1185
Vink JM *see* **Pergadia ML**
Vitaro F *see* **Pingault J-B**
Volk DW *see* **Curley AA**
von dem Hagen EAH *see* **Fairchild G**
von der Goltz C *see* **Koopmann A**
von Esenwein SA *see* **Druss BG**
Voormolen EHJ *see* **Chow EWC**
Votolato N *see* **McKnight C**

W

Wachtel LE *see* **Dhossche D**
Waid LR *see* **Anton RF**
Wakjer S: The Council on Minority Mental Health and Health Disparities (off acts). *Fe* 224
Walker EF *see* **Addington J**
Walling D *see* **Green MF**
Walsh BT *see* **Marsh R**
Wang G-b *see* **Zhang X-l**
Wang J *see* **Zhang X-l**

Wang K *see* **Levinson DF**
Wang P *see* **Marsh R**
Wang S-C *see* **Wu C-S**
Wang X-Q *see* **Johnson BA**
Wang Z, **Maia TV**, **Marsh R**, **Colibazzi T**, **Gerber A**, **Peterson BS**: The neural circuits that generate tics in Tourette's syndrome. *De* 1326–1337
Warden D *see* **Rush AJ**
Warner CH, **Appenzeller GN**, **Parker JR**, **Warner CM**, **Hoge CW**: Effectiveness of mental health screening and coordination of in-theater care prior to deployment to Iraq: a cohort study. *Ap* 378–385 (correction, *Je* 652)
Warner CM *see* **Warner CH**
Wasserstein J *see* **Solanto MV**
Waters BM *see* **Romo CA**
Webb BT *see* **Breen G**
Weddle C *see* **Shaw P**
Wei C *see* **Chow EWC**
Weiden PJ: Switching antipsychotic medications: not enough, too often, or just right? (editorial). *Se* 882–884
Weiner E: Lessons from Jimmy (introspections). *Mr* 243–244
Weiser M: Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase (editorial). *Au* 761–763
Weiser M: Response to Woods, McGlashan: The risk-benefit ratio of the proposed DSM-5 attenuated psychosis syndrome (letter). *De* 1338
Weisinger B *see* **Mattai A**
Weiss KJ: Albert Deutsch, 1905–1961 (image, psych). *Mr* 252
Weiss RD: bk rev, Galanter M, Kleber HD: Psychotherapy for the Treatment of Substance Abuse. *Jy* 755–756
Weiss RD: bk rev, Levounis P, Arnaout B, eds: Handbook of Motivation and Change: A Practical Guide for Clinicians. *Fe* 215
Weissman MM *see* **Wickramaratne P**
Weissman MM: Can epidemiology translate into understanding major depression with borderline personality disorder? (editorial). *Mr* 231–233
Wells A, **Fisher P**: Metacognitive therapy without metacognition: a case of ADHD (letter). *Mr* 327
Wells TT *see* **Beevers CG**
Wender P, **Occhiogrosso M**: Sir Richard Steele, 1672–1729: early traumatic loss and adult sequelae (image, psych). *Ap* 355
Werge T *see* **Ingason A**
Westen D *see* **Shedler J**

Wexler E, **Fogel BL**: New-onset psychosis in a patient with spinocerebellar ataxia type 10 (letter). *De* 1339–1340
White T: bk rev, Lenzenweger MF: Schizotypy and Schizophrenia: The View from Experimental Psychopathology. *Mr* 334–335
Whooley MA *see* **Duivis HE**
Wickramaratne P, **Gameroff MJ**, **Pilowsky DJ**, **Hughes CW**, **Garber J**, **Malloy E**, **King C**, **Cerda G**, **Sood AB**, **Alpert JE**, **Trivedi MH**, **Fava M**, **Rush AJ**, **Wisniewski S**, **Weissman MM**: Children of depressed mothers 1 year after remission of maternal depression: findings from the STAR*D-Child study. *Je* 593–602
Wiedemann K *see* **Agorastos A**
Wilkinson P, **Kelvin R**, **Roberts**, **Dubicka B**, **Goodyer I**: Clinical and psychosocial predictors of suicide attempts and nonsuicidal self-injury in the Adolescent Depression Antidepressants and Psychotherapy Trial (ADAPT). *My* 495–501
Willemen HLD *see* **van Zuiden M**
Willemssen G *see* **Pergadia ML**
Winstead D *see* **Lieberman JA**
Wise TN, **Renner JA**: The Council on Adult Psychiatry (off acts). *Fe* 219
Wisniewski S *see* **Rush AJ**; **Wickramaratne P**
Witt S *see* **Dong L**
Wodarz N *see* **Dong L**
Woods SW *see* **Addington J**
Woods SW, **McGlashan TH**: The risk-benefit ratio of the proposed DSM-5 attenuated psychosis syndrome (letter). *De* 1338
Woodward ND, **Cowan RL**, **Park S**, **Ansari MS**, **Baldwin RM**, **Li R**, **Doop M**, **Kessler RM**, **Zald DH**: Correlation of individual differences in schizotypal personality traits with amphetamine-induced dopamine release in striatal and extrastriatal brain regions. *Ap* 418–426
Woody GE *see* **Fishman MJ**
Wray NR *see* **Pergadia ML**
Wright TM *see* **Anton RF**
Wu C-S, **Wang S-C**, **Cheng Y-C**, **Gau SS-F**: Association of cerebrovascular events with antidepressant use: a case-crossover study. *My* 511–521
Wu L-T *see* **Fishman MJ**
Wu Q *see* **Lui S**
Wykes T, **Huddy V**, **Cellard C**, **McGurk SR**, **Czobor P**: A meta-analysis of cognitive remediation for schizophrenia: methodology and effect sizes (reviews and overviews). *My* 472–485

X

Xiao X *see* **Li M**
Xie H *see* **Drake RE**
Xu J *see* **Meltzer HY**

Y

Yager J, Gelenberg J, Fochtmann LJ: Response to Marcus, Sanchez, Frost, McQuade: Aripiprazole adjunctive to antidepressant therapy (letter). Fe 211
Yakovleva T *see* **Dong L**
Yang X *see* **Lui S**
Yang Y *see* **Foland-Ross LC**
Ye K *see* **Andero R**

Yershova KV *see* **Posner K**
Yin L *see* **Li M**
Yolken RH *see* **Prasad KM**
Yoon JH *see* **Ursu S**
Yorks D *see* **Surman GBH**
Yudofsky SC: bk rev, Williamson PC, Allman JM: The Human Illnesses: Neuropsychiatric Disorders and the Nature of the Human Brain. Se 993–994
Yurgelun-Todd DA *see* **Kim N**

Z

Zaheer J *see* **Law SF**
Zald DH *see* **Woodward ND**
Zhang N *see* **Levinson DF**

Zhang X-l, Shi J, Zhao, L-y, Sun L-l, Wang J, Wang G-b, Epstein DH, Lu L: Effects of stress on decision-making deficits in formerly heroin-dependent patients after different durations of abstinence. Je 610–616

Zhao L *see* **Druss BG**
Zhao L-y *see* **Zhang X-l**
Zheng L *see* **Vigen CLP**
Zhu Q *see* **Pergadia ML**
Zill P *see* **Dong L**
Zimmerman M: bk rev, Regier DA, Narrow WE, Kuhl EA, Kupfer DJ, eds: The Conceptual Evolution of DSM-5. Oc 1122

Zimmermann P, Brückl T, Nocon A, Pfister H, Binder EB, Uhr M, Lieb R, Moffitt TE, Caspi A, Holsboer F, Ising M: Interaction of *FKBP5* gene variants and adverse life events in predicting depression onset: results from a 10-year prospective community study. Oc 1107–1116
ZODIAC Investigators *see* **Strom BL**
Zuvekas SH *see* **Garfield RL**
Zwiers M *see* **Hoogman M**